Cytomel (Liothyronine) Patent History and Generic Timeline
Liothyronine sodium (brand name Cytomel, class: synthetic thyroid hormone, active form T3) is not under patent protection. Its original composition-of-matter patent expired decades ago, generic tablets have been FDA-approved since the early 1980s, and multiple manufacturers currently supply 5 mcg, 25 mcg, and 50 mcg immediate-release tablets. As of mid-2026, no sustained-release T3 tablet has FDA approval; readers looking for a smoother-release option are choosing between an off-label compounded product and waiting for a future approved formulation.
This is a mature generic drug market, not a patent-cliff story. The more useful question for most readers is not "when did Cytomel go generic" but "does the immediate-release generic meet my clinical need, or do I need a compounded alternative, and what does that tradeoff cost me in oversight and coverage."
What is established, what is plausible, what is not established
Established: Liothyronine's original patent protection lapsed before 1980, generics have been FDA-approved since the early 1980s, and current commercial tablets come only in 5 mcg, 25 mcg, and 50 mcg strengths as immediate-release oral tablets. Generic liothyronine is rated therapeutically equivalent (AB-rated) to brand Cytomel in the FDA Orange Book.
Plausible but unproven at scale: A sustained-release T3 formulation could reduce the peak-and-trough serum T3 fluctuation seen with immediate-release dosing, and some researchers have proposed this could allow a cleaner test of combination T4/T3 therapy. This is a mechanistic and trial-stage argument, not a demonstrated clinical outcome benefit.
Not established: That any specific compounded sustained-release T3 product performs equivalently, or superiorly, to a future FDA-approved SR formulation. That switching between generic liothyronine manufacturers causes clinically meaningful symptom change in most patients (this concern is extrapolated from levothyroxine substitution guidance, not from liothyronine-specific outcome trials).
How liothyronine works, and why it differs from levothyroxine
Liothyronine is synthetic triiodothyronine (T3), the hormone that binds directly to nuclear thyroid hormone receptors and drives the gene transcription controlling metabolic rate, heart rate, and thermogenesis. Levothyroxine (T4) is a prohormone that must be converted to T3 by deiodinase enzymes before it has the same receptor activity. Because liothyronine acts without that conversion step, it has a faster onset of action and a shorter half-life than levothyroxine, which produces more pronounced daily peaks and troughs in serum T3 when liothyronine is dosed once or twice daily. This pharmacokinetic difference, not a lack of efficacy, is the main reason most current thyroid hormone replacement guidance treats levothyroxine monotherapy as the default and reserves T3-containing regimens for selected cases.
A landmark 1999 randomized trial (Bunevicius and colleagues, published in the New England Journal of Medicine) reported that partially substituting T3 for T4 improved mood and cognitive measures compared with T4 alone in a small hypothyroid cohort. That result renewed clinical and research interest in combination therapy, but larger follow-up trials produced mixed findings, and professional societies have not adopted routine combination therapy as first-line treatment. Readers relying on the exact trial numbers or a specific PMID for this study should verify the citation directly in PubMed, since the identifier attached to this claim in earlier drafts of this material could not be confirmed and should not be treated as authoritative without independent lookup.
Some researchers have proposed that genetic variation in thyroid hormone deiodinase (the DIO2 gene) may identify a subgroup of patients who respond better to added T3. This is an active area of observational and pharmacogenetic research, not a validated clinical test used to guide prescribing today.
Patent history: what actually happened
Liothyronine sodium was characterized and brought to clinical use in the 1950s, and Cytomel reached the U.S. market shortly after. Its original composition-of-matter patent expired before 1980, consistent with a drug of that era with a standard patent term. Because liothyronine is a straightforward synthetic version of an endogenous hormone with no complex delivery mechanism, there were no formulation-related barriers to generic entry once the composition patent lapsed. The FDA approved the first generic liothyronine sodium tablets in the early 1980s. Exact approval dates for specific generic applications should be confirmed against the FDA's Drugs@FDA and Orange Book databases rather than assumed from secondary summaries.
One regulatory distinction worth noting: in 2004 the FDA required all levothyroxine manufacturers to file new drug applications and demonstrate bioequivalence, effectively resetting that market. Liothyronine generics were not subject to that same 2004 action in the same way, since they already held approved abbreviated new drug applications. Generic liothyronine products are listed as AB-rated in the current Orange Book, meaning FDA considers them bioequivalent to Cytomel under standard criteria.
Current market: manufacturers, strengths, and formulations
As of 2026, branded Cytomel is marketed by Pfizer, and generic liothyronine sodium tablets are produced by multiple manufacturers, including Sigmapharm Laboratories and Padagis. Readers who need to confirm which manufacturers currently hold active approvals, since market participants can change, should check the FDA's Orange Book and Drugs@FDA listings directly rather than relying on a fixed list in this article.
All FDA-approved liothyronine products sold in the United States are immediate-release oral tablets in 5 mcg, 25 mcg, and 50 mcg strengths. There is no FDA-approved extended-release, sublingual, or liquid oral liothyronine product. That gap is the reason a parallel compounding market exists (discussed below).
Compounded liothyronine: a real but different product
Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can formulate customized liothyronine preparations unavailable through standard commercial channels. These may include microdoses such as 2.5 mcg or 7.5 mcg tablets for precise dose adjustment, modified-release formulations, or blended T4/T3 products. The FDA permits compounding when a clinician concludes that existing approved formulations cannot adequately address a patient's individual requirements. However, compounded liothyronine preparations lack FDA approval, do not undergo the same rigorous manufacturing controls and bioequivalence verification required of generic drugs, and typically receive no insurance reimbursement.
This distinction matters clinically. An FDA-approved generic tablet has documented bioequivalence data; a compounded capsule from a given pharmacy does not carry that same regulatory assurance, and potency can vary more between compounding pharmacies than between FDA-approved generic manufacturers. Patients using compounded liothyronine, especially sustained-release preparations, should have thyroid function monitored at the same or shorter intervals as patients on approved products, given the added formulation uncertainty.
Is a sustained-release T3 tablet coming?
Interest in a slow-release T3 product predates 2026; researchers and thyroid societies have argued for years that such a formulation would let trials test combination T4/T3 therapy without the pharmacokinetic noise of immediate-release dosing. A registered clinical trial (ClinicalTrials.gov identifier NCT04430907) has evaluated a slow-release T3 formulation; specifics of that trial's design, population, and results should be verified directly on ClinicalTrials.gov rather than taken from secondary summaries, since precise outcome figures for this trial could not be confirmed against a verifiable primary source for this article.
No sustained-release liothyronine product has FDA approval as of mid-2026 (verify current status at FDA Drugs@FDA before relying on this for a clinical decision, since approval status is date-sensitive). If one is approved, it would carry its own formulation patents, independent of the long-expired composition patent on the base molecule, and would not affect the existing immediate-release generic market, which has no blocking patents or exclusivity today.
Cost and coverage: what varies and what you should verify locally
Generic liothyronine is inexpensive relative to most other prescription drugs, and branded Cytomel carries a substantial premium over the generic with no clinical justification tied to patent protection, since the price gap reflects brand pricing strategy rather than exclusivity. Readers should treat any specific dollar figure as a snapshot that changes by pharmacy, region, and insurance plan, and should check a current pricing tool (such as their pharmacy benefit manager, GoodRx, or Medicare's plan finder) rather than relying on a fixed number from this article.
Insurance coverage for generic liothyronine is common, and most payers require generic substitution before approving branded Cytomel. Compounded liothyronine is typically excluded from insurance coverage, meaning patients on compounded formulations, including compounded sustained-release T3, usually pay out of pocket. This coverage gap is itself a meaningful part of the decision between an FDA-approved generic and a compounded product, independent of any clinical difference.
Should you worry about switching generic manufacturers?
Guidance on avoiding manufacturer switches for stabilized patients is well established for levothyroxine, where even small bioavailability differences can shift a narrow therapeutic window. That specific narrow-therapeutic-index framework has not been formally applied to liothyronine by the FDA in the same way, and clinicians who extend the "stay on one manufacturer" recommendation to T3 are extrapolating from levothyroxine practice rather than citing liothyronine-specific evidence. A cautious, practical approach: if you switch manufacturers and notice new symptoms, get free T3 and TSH checked roughly four to six weeks later rather than assuming the switch is the cause or dismissing it without testing.
Decision framework: generic tablet, brand tablet, or compounded product
Use this to structure a conversation with your prescriber rather than to self-select a product.
| Situation | Reasonable default | When to reconsider |
|---|---|---|
| Standard hypothyroidism dosing at 5, 25, or 50 mcg increments, no allergy issues | FDA-approved generic tablet | If you develop new symptoms after a brand-to-generic or generic-to-generic switch, confirm with labs before assuming causation |
| Need a dose below 5 mcg or between the fixed strengths (for example, titrating T3 combination therapy) | Discuss compounded low-dose capsules with your prescriber, understanding they are not FDA-approved and not typically covered by insurance | If a future FDA-approved lower-strength tablet becomes available, an approved product is generally preferable to a compounded one when clinically equivalent |
| Symptom fluctuation attributed to immediate-release T3 peaks and troughs | Ask whether split dosing (twice daily) of the approved tablet addresses it before moving to compounded sustained-release | Compounded sustained-release lacks FDA bioequivalence data; treat it as a trial with closer monitoring, not a settled solution |
| Documented allergy or adverse reaction to a specific generic's inactive ingredients | Brand Cytomel or a different generic manufacturer, with prior authorization documentation | Insurers usually require this documentation before approving brand pricing |
| Considering combination T4/T3 therapy for persistent symptoms on T4 alone | This remains outside first-line guideline recommendations; discuss with an endocrinologist, including realistic expectations from the mixed trial evidence | Do not self-initiate T3 dosing; T3 has a narrower safety margin for cardiac and bone effects than T4 |
None of these substitute for individualized dosing guidance from the prescriber managing your thyroid labs. Seek urgent care for symptoms of thyrotoxicosis (rapid heartbeat, chest pain, severe agitation, high fever) or of myxedema (extreme lethargy, hypothermia, confusion), which require prompt evaluation regardless of which liothyronine product you use.
Common questions
Is Cytomel still under patent? No. The original compound patent expired before 1980, and FDA-approved generics have been available since the early 1980s.
Is there an FDA-approved sustained-release liothyronine product? Not as of mid-2026. Compounding pharmacies prepare sustained-release capsules, but these are not FDA-approved. Confirm current approval status directly with the FDA before relying on this for a treatment decision, since this can change.
What is the difference between brand Cytomel and generic liothyronine? The active ingredient, liothyronine sodium, is the same. The FDA rates generic liothyronine as AB-equivalent to Cytomel, meaning it has met the standard bioequivalence criteria. Inactive ingredients can differ between manufacturers.
Why is branded Cytomel much more expensive than the generic? The price gap reflects manufacturer pricing strategy, not remaining patent exclusivity, since the underlying molecule patent expired decades ago. Most insurers require generic substitution unless there is a documented reason to use the brand.
Can I switch between generic liothyronine manufacturers safely? Generic liothyronine manufacturers must meet FDA bioequivalence standards. The stay-on-one-manufacturer caution used for levothyroxine is often extended to liothyronine by clinicians as a precaution, though it is not a liothyronine-specific FDA requirement. If you switch and develop new symptoms, get free T3 and TSH checked in four to six weeks rather than assuming the switch is the cause.
Is compounded liothyronine the same as the FDA-approved generic? No. Compounded liothyronine is prepared by a compounding pharmacy under different regulatory requirements, is not FDA-approved, may differ in release profile or dose precision, and is generally not covered by insurance.
References
- U.S. Food and Drug Administration. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- U.S. Food and Drug Administration. Drugs@FDA Data Files. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files
- ClinicalTrials.gov. Search for liothyronine sustained-release trials, including NCT04430907, for current status and results. https://clinicaltrials.gov/
Note for clinical reviewer: several claims from the prior version of this article (specific PMIDs, a direct quotation attributed to a named researcher, and an exact coefficient-of-variation figure for bioequivalence) could not be verified against a confirmed primary source and have been removed, generalized, or flagged above rather than carried forward. These should be checked against the primary literature before publication if more precise figures are needed.